324 |
Show, Ask & Listen : Can We Manage PVL? |
Jeehoon Kang |
Aug. 01. 22 |
323 |
Hands-on Training with Operator |
Jung-Sun Kim |
Aug. 01. 22 |
322 |
½Ã¼ú Áß TEE Æò°¡ ³ëÇÏ¿ì |
Dae-Hee Kim |
Aug. 01. 22 |
321 |
Mitraclip À» À§ÇÑ ½Ã¼ú½Ç Áغñ, Puncture to Close |
Do-Yoon Kang |
Aug. 01. 22 |
320 |
´ë»ó ȯÀÚ Ã£±â: ½ÉÃÊÀ½ÆÄ ½ºÅ©¸®´×ÀÇ ¸ðµç °Í |
Seung-Ah Lee |
Aug. 01. 22 |
319 |
Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic? |
Duk-Woo Park |
Aug. 01. 22 |
318 |
Next Target for Valve Pharmacology: Mechanical Valve Revisited with NOAC - RENOVATE Trial |
Joon Bum Kim |
Aug. 01. 22 |
317 |
Key Message from the ADAPT-TAVR Trial: What We Learned? |
Duk-Woo Park |
Aug. 01. 22 |
316 |
Optimal Indication for Cerebral Embolic Protection for TAVR: Insights from the TVT Registry |
David Joel Cohen |
Aug. 01. 22 |
315 |
Balloon-expandable vs. Self-expandable TAVR for Bicuspid Valve: When or How? |
James Flaherty |
Aug. 01. 22 |